SBIR-STTR Award

Development of SupraGuard ETT, a Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia
Profile last edited on: 1/31/2022

Program
SBIR
Agency
NIH | NHLBI
Total Award Amount
$225,135
Award Phase
1
Principal Investigator
David J Vachon
Activity Indicator

Company Information

Iasis Molecular Sciences LLC

3305 East Moran Vista Lane
Spokane, WA 99223
   (509) 844-2734
   djvachon@iasismolecular.com
   www.iasismolecular.com
Multiple Locations:   
Congressional District:   05
County:   Spokane

Phase I

Phase I year
2021
Phase I Amount
$225,135
The Centers for Disease Control and Prevention (CDC) reports that preventing ventilator associated pneumonia (VAP), as opposed to treating the acquired infection, is a critical and unmet need. To respond to this need, Iasis Molecular Sciences will leverage strong preliminary data obtained for proprietary antimicrobial compositions (composites). Excellent antimicrobial performance and material cytocompatibility could be beneficial in the creation of a next generation endotracheal tube that could substantively reduce VAP. SupraGuardTM ETT is an advanced device wholly constructed from an antimicrobial composite designed to kill microorganisms known to cause VAP. The compositions are effective against organisms intraluminally or those located in subglottic fluids that have pooled above the cuff while maintaining excellent mechanical characteristics.The proposed research will address ETT composite formulation, composite processing, microbial inactivation, composite biocompatibility and stability, and ETT cuff viability. The major specific aims of the proposed research include: 1.) Finalizing SupraGuardTM Next Generation Antimicrobial Endotracheal Tube & Cuff Materials Development, 2.) Measure the Antibacterial & Antifungal Effectiveness of the SupraGuardTM Composites. 3.) Evaluate the In Vitro & In Vivo Biocompatibility of SupraGuardTM Composites. There is significant commercial potential for our product, as the antimicrobial-coated ETT component of the ETT market was valued at $1.84B in 2018 and whereby the majority of antimicrobial ETTs are silver-coated ETTs. However, there are no products today that possess effective antimicrobial ETT cuffs that can effectively kill pathogens. Public Health Relevance Statement Project Narrative Ventilator-associated pneumonia (VAP) places a substantial burden on healthcare systems because of its frequency, associated morbidity and the cost of treatment. Estimates of VAP in mechanically ventilated patients is 9-27 %. VAP is the second most common HAI and the most common infection of those undergoing mechanical ventilation. We propose to develop and test innovative antimicrobial composites to be used as the foundation of a next generation antimicrobial endotracheal tube to prevent VAP.

Project Terms:
preventing ; prevent ; Diameter ; Caliber ; Address ; Data ; in vivo ; Invaded ; Small Business Innovation Research Grant ; SBIR ; Small Business Innovation Research ; Characteristics ; Molecular ; Modification ; Development ; developmental ; design ; designing ; next generation ; catheter associated UTI ; catheter associated urinary tract infection ; urinary tract catheter infection ; nanoparticle ; nano particle ; nano-sized particle ; nanosized particle ; pathogen ; innovation ; innovate ; innovative ; antimicrobial ; anti-microbial ; airway epithelium ; Implant ; commercial application ; ventilator-associated pneumonia ; ventilator-acquired pneumonia ; metallicity ; Formulation ; improved outcome ; Modulus ; healthcare-associated infections ; health care-associated infections ; ventilation ; Accounting ; Affect ; Antifungal Agents ; Antifungal Drug ; Therapeutic Fungicides ; anti-fungal ; anti-fungal agents ; anti-fungal drug ; antifungals ; Asia ; Bacteria ; Biocompatible Materials ; Biomaterials ; biological material ; Cation Exchange Resins ; Cation Exchangers (Resins) ; Cause of Death ; Centers for Disease Control and Prevention (U.S.) ; CDC ; Centers for Disease Control ; Centers for Disease Control and Prevention ; United States Centers for Disease Control ; United States Centers for Disease Control and Prevention ; Emergency Medicine ; Engineering ; Environment ; Epithelial Cells ; Exhibits ; Family ; Foundations ; Goals ; Healthcare Systems ; Health Care Systems ; In Vitro ; Incidence ; Infection ; Intubation ; Ion Exchange Resins ; Length of Stay ; Number of Days in Hospital ; hospital days ; hospital length of stay ; hospital stay ; Medical Device ; Microbiology ; Morbidity - disease rate ; Morbidity ; North America ; Organism ; living system ; Legal patent ; Patents ; Patients ; Pneumonia ; Polymers ; Powder dose form ; Powders ; pressure ; Research ; Research Design ; Study Type ; study design ; Science ; Silicones ; Silver ; Ag element ; Technology ; Testing ; Time ; Tissues ; Body Tissues ; Trachea ; Trachea Proper ; windpipe ; Tracheostomy procedure ; Tracheostomy ; Work ; Measures ; Microbial Biofilms ; biofilm ; Device Designs ; Healthcare ; health care ; Treatment Cost ; Tube ; base ; Mechanical ventilation ; mechanical respiratory assist ; mechanically ventilated ; Surface ; Clinical ; Phase ; Nosocomial Infections ; Hospital Infections ; Hospital acquired infection ; institutional infection ; Hospital Costs ; Hospitalization cost ; Ensure ; Chemicals ; Anti-Bacterial Agents ; Antibacterial Agents ; anti-bacterial ; antibacterial ; fluid ; liquid ; Liquid substance ; Filamentous Fungi ; Molds ; mechanical ; Mechanics ; Hour ; Frequencies ; Gastric Secretion ; gastric secretion substance ; Oral ; Reaction ; Treatment Period ; treatment days ; treatment duration ; microorganism ; lower respiratory tract ; Lower respiratory tract structure ; Operative Procedures ; Surgical ; Surgical Interventions ; Surgical Procedure ; surgery ; Operative Surgical Procedures ; meetings ; biocompatibility ; biomaterial compatibility ; Performance ; success ; endotracheal ; microbial ; Toxicities ; Toxic effect ; Structure ; novel ; Prevention ; Devices ; Reporting ; Lung Parenchyma ; Lung Tissue ; Structure of parenchyma of lung ; Regulation ; monolayer ; Pathogenicity ; Pharmaceutical Agent ; Pharmaceuticals ; Pharmacological Substance ; Pharmacologic Substance ; Effectiveness ;

Phase II

Phase II year
---
Phase II Amount
---